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Role of LD proteins in obesity-associated insulin 
resistance, diabetes, and lipoatrophic diabetes
LD proteins in lipoatrophic diabetes. Plin1 and members of the PAT 
































































































Alterations in LD proteins in adipocytes result in increased lipolysis and promote insulin resistance. In lipoatrophic and obese humans, reduced 
expression of PLIN1, CIDEC, or CIDEA in adipocytes results in constitutive release of fatty acids (FA). These fatty acids act locally and enter the 
bloodstream, where they activate inflammatory pathways, promote ectopic lipid deposition in peripheral tissues, and cause insulin resistance. 
The released fatty acids act locally to promote insulin resistance and inflammation by: (a) engaging TLRs, resulting in activation of MAPK signal-
ing pathways and release of inflammatory mediators, which block insulin actions on lipolysis and glucose uptake; (b) recruiting macrophages that 
amplify the inflammatory response; and (c) inducing ectopic lipid deposition in hepatocytes and skeletal muscle cells and activating inflammatory 
pathways. A reduction in PLIN1 increases constitutive lipolysis by allowing CGI-58, normally associated with PLIN1, to activate LD-associated 
and non-LD–associated ATGL. Reductions in CIDEA or CIDEC enhance lipolysis by unclear mechanisms. In humans, genetic alterations in 
seipin and caveolin-1 reduce adipose tissue mass, resulting in lipodystrophy.
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Plin2 expression  reduces  lipid hydrolysis was  that  it  excludes 



























Liver LD increases in obesity are linked to hepatic steatosis and insulin resistance. Fatty acids from the diet or adipocyte lipolysis result in 
accumulation of neutral lipids in LD in hepatocytes and incorporation of PLIN2, PLIN3, CIDEA, CIDEB, CIDEC, and ATGL on the LD surface. In 
humans, PLIN1 is also found on hepatic LDs in individuals with NAFLD and NASH. Increased fatty acid accumulation and LD formation are in 
general associated with increased accumulation of diacylglycerol (DAG) and inflammatory cytokines. DAG activates atypical PKC, and fatty acids 
and cytokines activate inflammatory signaling pathways, which cumulatively block the actions of IRS-1 and -2 and promote insulin resistance. 
It is possible that DAG as well as TAG accumulate in LDs. In hepatocytes, insulin resistance is marked by increased hepatic gluconeogenesis 
and reduced glycogen formation. Notably, mutations in the phospholipase PNPLA3 result in hepatic steatosis.
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